Lilly Buys Psychedelics Maker Atai Beckley for $2.8B
Eli Lilly unveils a landmark $2.8 billion cash deal to acquire Atai Beckley, aiming to push a DMT-like therapy for tr...
Not all retirees benefit equally from Target Date Funds. This guide points out scenarios and preferences where avoidance may be wise.
27,346 articlesEli Lilly unveils a landmark $2.8 billion cash deal to acquire Atai Beckley, aiming to push a DMT-like therapy for tr...
Bitcoin trades below the $70,000 mark as bear market fears grow and investors watch a potential CLARITY Act vote. Thi...
Samsung and Apple tied on annual smartphone production in TrendForce’s data, sparking fresh market debate on leadersh...
Mortgage rates surged to a 3-month high, reshaping the investment landscape. A handful of stocks—mortgage servicers, ...
Apple signals a strategic pivot, moving its flagship away from the iPhone toward ambient computing with Vision Pro an...
A fresh modeling study puts the economic toll of long COVID at over $8 billion from 2025 to 2027, driven largely by l...
Bitcoin topped in late 2025, then pulled back as macro forces and ETF flows shifted. This piece breaks down why 2027 ...
Two Maverick Capital co-CIOs warn of an air pocket between AI infrastructure and productivity, signaling a market tur...
A historic White House ceremony tied a market milestone to a child-focused investing program. Treasury confirms $1.4 ...
Tech stocks pulled back this week as margin risk reemerged amid a cooling chip cycle. Investors who bet on leverage w...
Bitcoin slipped to a 17-day low as risk-off sentiment reasserted itself in crypto markets. This report shows which as...
Axiamatic has secured $54 million in new funding to scale its AI-powered transformation platform, aimed at curbing bu...